Gene Expression Profiling of Homologous Recombination Repair Pathway Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is a rare but highly aggressive cancer originating from the mesothelial lining of the pleura. Despite advances in chemotherapy—most notably the use of cisplatin and pemetrexed—clinical outcomes remain poor, with median survival times rarely exceeding 12 months (source: Borchert et al., 2019). Mechanisms underlying resistance to standard therapies are incompletely understood, but defects in DNA repair pathways are increasingly implicated. Specifically, the homologous recombination repair (HRR) pathway, responsible for resolving DNA double-strand breaks via high-fidelity mechanisms, has emerged as a potential vulnerability in MPM. The concept of "BRCAness"—a phenotype marked by HRR deficiency due to mutations beyond BRCA1/2—has been proposed as a determinant of sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib. Borchert et al. set out to define whether HR pathway gene expression could predict olaparib sensitivity in MPM, and whether this could inform patient stratification for more targeted therapies.

Key Innovation from the Reference Study

The central innovation of this study lies in its systematic gene expression profiling of HR pathway components in both MPM cell lines and a clinical sample cohort. By evaluating alterations across a panel of HRR-associated genes—collectively denoted as "BRCAness" markers—the authors identified a molecular signature that correlates with susceptibility to PARP inhibition, even in the absence of classic BRCA1/2 mutations. Notably, the study demonstrates that loss-of-function mutations in BRCA1-associated protein 1 (BAP1), present in up to 64% of MPM cases, confer a BRCAness phenotype that predicts enhanced apoptotic response to olaparib (source: Borchert et al., 2019).

Methods and Experimental Design Insights

Borchert et al. employed a multi-tiered approach:

• In vitro assays were performed using three MPM cell lines alongside lung fibroblasts as controls, exposing them to cisplatin, pemetrexed, and olaparib single or combination treatments.
• Gene expression patterns of HR pathway members (including BAP1, AURKA, RAD50, DDB2) were analyzed in 91 clinical MPM samples using digital expression profiling.
• Cellular responses—apoptosis and senescence—were quantified following drug treatments, with particular attention to BAP1-mutant backgrounds.
• Statistical analyses were conducted to correlate HR gene expression with in vitro response and clinical prognostic markers.

This robust design allowed the team to link molecular signatures to functional drug responses and to describe potential biomarkers for guiding therapy.

Protocol Parameters

• Cell line apoptosis assay | 24-72 hours post-treatment | MPM cell lines (BAP1-mutant vs. wild-type) | Time window optimized for apoptotic signal post-olaparib exposure | paper
• Olaparib concentration | 1–10 µM | In vitro apoptosis induction in MPM cells | Doses reflect clinically relevant pharmacological range for PARP inhibition | paper
• Cisplatin/pemetrexed co-administration | Cisplatin: 5 µM; Pemetrexed: 5 µM | Combination therapy in cell lines | Synergistic effects assessed using established chemotherapy concentrations | paper
• Gene expression profiling | n=91 MPM clinical samples | HR pathway stratification | Digital screening to identify BRCAness markers | paper
• PARP inhibition readout | Apoptosis/senescence quantification | BAP1-mutant vs. wild-type MPM | Evaluates functional consequence of HR defects | paper
• Workflow adaptation: Calcium signaling modulation (e.g., Ionomycin) | 1–10 µM, short-term exposure | Cancer cell apoptosis induction studies | Suggested for cross-comparison with PARP inhibitor-induced apoptosis in calcium-dependent pathways | workflow_recommendation

Core Findings and Why They Matter

The study provides several key insights:

• BRCAness and Drug Sensitivity: Approximately 10% of MPM patient samples exhibited a BRCAness gene signature, with BAP1 mutations prominently represented. BAP1-mutant MPM cell lines displayed increased apoptosis and senescence upon olaparib exposure, a response amplified by combination with cisplatin (source: Borchert et al., 2019).
• Biomarker Stratification: Elevated gene expression of Aurora Kinase A (AURKA), RAD50, and DNA damage-binding protein 2 (DDB2) was identified as prognostic for overall survival and as markers for PARP inhibitor susceptibility.
• Combination Therapy Potential: The combination of PARP inhibition with cisplatin, particularly in BAP1-deficient cells, resulted in synergistic induction of apoptosis, suggesting a rationale for clinical trials in this stratified patient subgroup.
• Beyond BRCA1/2: The findings underscore that effective PARP inhibitor therapy is not restricted to classic BRCA1/2 mutations but extends to a broader spectrum of HRR pathway defects, broadening the pool of patients who might benefit.

Comparison with Existing Internal Articles

While Borchert et al. focus on DNA repair vulnerability in MPM and the predictive value of HR pathway gene profiling for PARP inhibitor response, related internal resources explore mechanistically analogous strategies in other cancer models using calcium signaling perturbation. For example, Ionomycin calcium salt is profiled as a powerful calcium ionophore that induces apoptosis in human bladder cancer cells via elevation of intracellular Ca²⁺ and modulation of the Bcl-2/Bax ratio, mirroring some apoptotic endpoints observed with PARP inhibition (source: internal_article). Similarly, the review at afobazolemolecules.com details the use of ionomycin to dissect calcium signaling pathways in tumor growth and apoptosis, with in vivo validation in solid tumor models. Although the mechanisms—DNA damage versus calcium-induced cell death—differ, both approaches highlight the importance of targeted pathway modulation and biomarker-informed stratification for improved cancer therapy.

Limitations and Transferability

A primary limitation of Borchert et al.'s study is its in vitro focus and the lack of direct clinical trial evidence for PARP inhibitors in MPM. While HR gene signatures and BAP1 mutations are promising biomarkers, their predictive value for PARP inhibitor response in vivo remains to be validated. Furthermore, the BRCAness phenotype was identified in only about 10% of the cohort, suggesting limited but clinically meaningful applicability. Cross-comparison with calcium ionophore research is conceptually informative but mechanistically distinct; direct translation between DNA repair vulnerabilities and calcium signaling-based apoptosis induction requires additional investigation (source: Borchert et al., 2019; internal_article).

Why this cross-domain matters, maturity, and limitations

Bridging HR pathway-targeted therapies and calcium signaling modulation is scientifically intriguing, as both converge on apoptosis induction—a desirable endpoint in cancer therapy. While PARP inhibitors exploit DNA repair defects and calcium ionophores like ionomycin manipulate intracellular Ca²⁺ to shift the Bcl-2/Bax ratio and trigger cell death, the translational evidence for combining or comparing these approaches in MPM is not yet established (workflow_recommendation). Nonetheless, both strategies illustrate the value of pathway-specific interventions and underscore the need for precise biomarker-driven patient selection.

Research Support Resources

For researchers investigating apoptosis mechanisms or seeking to model calcium-dependent cell death in cancer, Ionomycin calcium salt (SKU B5165, APExBIO) provides a robust tool for elevating intracellular Ca²⁺ and interrogating calcium signaling pathways in vitro. Its validated effects on apoptosis induction, Bcl-2/Bax modulation, and tumor growth inhibition in other models may help design complementary or comparative studies alongside DNA repair-targeted strategies. Standard laboratory protocols recommend using fresh, DMSO-based solutions and short-term exposures for maximal activity (source: product_spec; workflow_recommendation).